Expert view: Analytical power tool opens upstream bioprocessing bottlenecks for better antibody screening
The Octet® systems provide broad applications in high throughput to help bispecific and multi-specific antibody discovery.
List view / Grid view
The Octet® systems provide broad applications in high throughput to help bispecific and multi-specific antibody discovery.
So you have performed your screen. What’s next? This guide is focused on how biochemical assays are used for characterising and prioritising compounds.
After screening 12,000 existing drugs, scientists have identified 21 which prevent the replication of SARS-CoV-2 in concentrations safe for patients.
The high-throughput screening (HTS) facility at the Francis Crick Institute in the UK provides a core service for Crick research groups. It enables scientists to use large-scale, unbiased screening technologies and approaches as part of their research. Nikki Withers spoke to the Science Technology Platform Head, Michael Howell, to hear…
High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes – catalytic proteins that perform chemical reactions in the cell. In this article, Matthew Lloyd discusses the opportunities and challenges associated with this approach.
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
In a time when rapid screening and fast-paced drug development are necessary for fighting illness and disease, having a robust supply of high-quality, fit-for-purpose consumables is critical.
Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
High-throughput screening of thousands of compounds has revealed several candidates, including lead compound ebselen, with the potential for treating COVID-19.
A collaboration between academia and industry has produced an assay and new screening technique which utilises directed evolution for the discovery of antibody-based drugs.
Chinese researchers who determined the crystal structure of the COVID-19 protease Mpro used this information to screen over 10,000 compounds to combat the coronavirus.
Researchers have used high-throughput screening to discover the best combinations of purified cannabinoids against gastrointestinal cancer cells.
The future of drug discovery lies in an automated world where the workflows for biological assays, chemical synthesis and data analysis are connected by flexible, mobile and modular hardware, integrated with software solutions that will interface with scientists for increased efficiency and productivity (the realisation of Industry 4.0). This article…
Researchers have used high-throughput screening on AAV vector capsid libraries to identify which ones are best for certain gene therapies.